News

lupus.bmj20h
P62 Machine learning approaches for prediction of renal flares in systemic lupus erythematosus: knowledge-driven models outperformed data-driven models
Objective Renal flares in patients with systemic lupus erythematosus (SLE) result in significant nephron loss. Thus, identification of reliable early signals of impending renal flares is anticipated ...
lupus.bmj1d
602 Childhood-onset Systemic Lupus Erythematosus: Long-term outcomes in a large multi-ethnic Ontario cohort
Background/Purpose The long-term morbidity and mortality of childhood-onset SLE (cSLE) after transition to adult care is not well documented. The present study aims to fill this knowledge gap by ...
lupus.bmj1d
Total Tubulointerstitial Score: a simple and effective predictor of long-term mortality and adverse renal outcomes in lupus nephritis
Objective Most studies focused on glomerular lesions in lupus nephritis (LN). However, the predictive value for tubulointerstitial lesions remains less well understood and controversial. Here, we ...
lupus.bmj1d
Development of a systemic lupus erythematosus cardiovascular risk equation
Objective Accelerated atherosclerosis remains the major cause of late death (after 5 years) in SLE. Yet, the ‘traditional’ cardiovascular risk equations (such as Framingham) consistently underestimate ...
lupus.bmj2d
1103 Dosage length of 2-deoxyglucose treatment has organ-specific transcriptome effects in a lupus-prone mouse model
Systemic lupus erythematosus (SLE) is the most common form of lupus; however, the development of new drugs for SLE has been limited, with only two drugs approved in the past 60 years. Recently, the ...
lupus.bmj2d
109 Long-term data on sirolimus treatment in lupus nephritis patients
Background and aims Preliminary data suggested efficacy of sirolimus in treatment of lupus nephritis (LN), but its long-term efficacy and tolerability data is lacking. Methods We reviewed Class III/IV ...
lupus.bmj2d
108 Iguratimod inhibits human b cell terminal differentiation in vitro and may benefit patients with refractory lupus nephritis
Background and Aims Iguratimod (IGT) is a small molecular immunomodulatory drug and has been approved for treating rheumatoid arthritis. In our previous work, IGT ameliorates lupus-like disease in MRL ...
lupus.bmj2d
178 Phase 2 trial of induction therapy with anti-CD20 (Rituximab) followed by maintenance therapy with anti-BAFF (Belimumab) in patients with active lupus nephritis
Background Despite case series suggesting efficacy, controlled trials of anti-CD20 in lupus and lupus nephritis (LN) have not meet their primary endpoints (Arthritis Rheum 2012;64:1215 and ...
lupus.bmj2d
The role of microparticles in the pathogenesis of SLE: a new look at an old paradigm
Winberg et al 1 present important new information on a story that began with the discovery of the lupus erythematosus (LE) cell phenomenon. As described in a truly landmark paper, Hargraves and ...
Lupus Science & Medicine2d
Impact of antiphospholipid antibodies on heart valve involvements in systemic lupus erythematosus: based on CSTAR cohort
Objective This study aims to evaluate the role of antiphospholipid antibodies (aPLs) in patients with SLE with heart valve ...
lupus.bmj3d
1507 The relationship between DNA methylation patterns and disease activity in a longitudinal multi-ancestral cohort of lupus patients
Background Epigenetic dysregulation is implicated in the pathogenesis of lupus. We performed a longitudinal analysis of DNA methylation in lupus patients and assessed epigenetic changes over time and ...
lupus.bmj3d
P130 Treatment of SLE with the immunoproteasome inhibitor KZR-616: results from the first 4 cohorts of the MISSION study, an open-label phase 1b dose escalation trial
Background Subcutaneous (SC) administration of KZR-616 (30 and 45 mg weekly [QW]) was demonstrated as safe and well-tolerated, and successfully achieved target levels of immunoproteasome inhibition in ...